Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab + Tuvonralimab induction and consolidation with chemoradiotherapy for locally advanced esophageal squamous cell carcinoma
ChiCTR2600130422Phase 2Not yet recruiting
- Sponsor
- The 2nd Affiliated Hospital of Chongqing Medical University
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iparomlimab and tuvonralimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by The 2nd Affiliated Hospital of Chongqing Medical University. Primary endpoint: 2-year progression-free survival rate. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2600130422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600130422.